1
|
Angelis YS, Sakellariou P, Fragkaki AG, Karnava S, Goula O, Kiousi P, Kioukia-Fougia N, Georgakopoulos C, Loui S, Chlapana F, Kletsas D. New long-standing metabolites of 17α-methyltestosterone are detected in HepG2 cell in vitro metabolic model and in human urine. Drug Test Anal 2024; 16:604-615. [PMID: 37903531 DOI: 10.1002/dta.3589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 08/17/2023] [Accepted: 10/08/2023] [Indexed: 11/01/2023]
Abstract
Novel metabolites of the anabolic androgenic steroid 17α-methyltestosterone have been detected in HepG2 cell in vitro metabolic model and in human urine. Their detection was accomplished through targeted gas chromatography-(tandem) mass spectrometry analysis that has been based on microscale synthesized standards. The related synthesis and the gas chromatography-(tandem) mass spectrometry characterization of the analytical standards are described. All newly presented metabolites have a fully reduced steroid A-ring with either an 17,17-dimethyl-18-nor-Δ13 structure or they have been further oxidized at position 16 of the steroid backbone. Metabolites with 17,17-dimethyl-18-nor-Δ13 structure may be considered as side products of phase II metabolic sulfation of the 17β-hydroxy group of methyltestosterone or its reduced tetrahydro-methyltestosterone metabolites 17α-methyl-5β-androstane-3α,17β-diol and 17α-methyl-5α-androstane-3α,17β-diol that produce the known epimeric 17β-methyl-5β-androstane-3α,17α-diol and 17β-methyl-5α-androstane-3α,17α-diol metabolites. The prospective of these new metabolites to increase detection time windows and improve identification was investigated by applying the World Anti-doping Agency TD2021IDCR criteria. The new metabolites, presented herein, complement the current knowledge on the 17α-methyltestosterone metabolism and in some cases can be used as additional long-term markers in the frame of sport doping drug testing.
Collapse
Affiliation(s)
- Yiannis S Angelis
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece
| | - Panagiotis Sakellariou
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece
| | - Argyro G Fragkaki
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece
| | - Sophia Karnava
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece
- Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece
| | - Olga Goula
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece
| | - Polyxeni Kiousi
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece
| | - Nassia Kioukia-Fougia
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece
| | | | - Stella Loui
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece
| | - Fotini Chlapana
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece
| | - Dimitris Kletsas
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece
- Laboratory of Cell Proliferation and Ageing, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece
| |
Collapse
|
2
|
Angelis YS, Fragkaki AG, Kiousi P, Sakellariou P, Christophoridis C. LC-MS/(MS) confirmatory doping control analysis of intact phase II metabolites of methenolone and mesterolone after Girard's Reagent T derivatization. Drug Test Anal 2023. [PMID: 36843443 DOI: 10.1002/dta.3465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 02/21/2023] [Accepted: 02/22/2023] [Indexed: 02/28/2023]
Abstract
In the present study, the application and evaluation of Girard's Reagent T (GRT) derivatization for the simultaneous detection and significantly important identification of different phase II methenolone and mesterolone metabolites by LC-MS/(MS) are presented. For the LC-MS analysis of target analytes two complementary isolation methods were developed; a derivatization and shoot method in which native urine is diluted with derivatization reagent and is injected directly to LC-MS and a liquid-liquid extraction method, using ethyl acetate at pH 4.5, for the effective isolation of both sulfate and glucuronide metabolites of the named steroids as well as of their free counterparts. For the evaluation of the proposed protocols, urine samples from methenolone and mesterolone excretion studies were analyzed against at least one sample from a different excretion study. Retention times, along with product ion ratios, were evaluated according to the WADA TD2021IDCR requirements, in order to determine maximum detection and identification time windows for each metabolite. Established identification windows obtained after LC-MS/(MS) analysis were further compared with those obtained after GC-MS/(MS) analysis of the same samples from the same excretion studies, for the most common analytes monitored by GC-MS/(MS). Full validation was performed for the developed derivatization and shoot method for the identification of methenolone metabolite, 3α-hydroxy-1-methylen-5α-androstan-17-one-3-glucuronide (mth3). Overall, the GRT derivatization presented herein offers a tool for the simultaneous sensitive detection of free, intact glucuronide and sulfate metabolites by LC-MS/(MS) that enhance significantly the detection and identification time windows of specific methenolone and mesterolone metabolites for doping control analysis.
Collapse
Affiliation(s)
- Yiannis S Angelis
- Doping Control Laboratory of Athens, Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos", Athens, Greece
| | - Argyro G Fragkaki
- Doping Control Laboratory of Athens, Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos", Athens, Greece
| | - Polyxeni Kiousi
- Doping Control Laboratory of Athens, Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos", Athens, Greece
| | - Panagiotis Sakellariou
- Doping Control Laboratory of Athens, Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos", Athens, Greece
| | - Christophoros Christophoridis
- Doping Control Laboratory of Athens, Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos", Athens, Greece
| |
Collapse
|
3
|
Kiousi P, Fragkaki AG, Kioukia-Fougia N, Angelis YS. Liquid chromatography-mass spectrometry behavior of Girard's reagent T derivatives of oxosteroid intact phase II metabolites for doping control purposes. Drug Test Anal 2021; 13:1822-1834. [PMID: 33942526 DOI: 10.1002/dta.3056] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 04/27/2021] [Accepted: 04/27/2021] [Indexed: 11/10/2022]
Abstract
Intact phase II steroid metabolites have poor product ion mass spectra under collision-induced dissociation (CID) conditions. Therefore, we present herein the liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/(MS)) behavior of intact phase II metabolites of oxosteroids after derivatization. Based on the fact that Girard's reagent T (GRT), as derivatization reagent, was both convenient and efficient in terms of the enhancement in the ionization efficiency and the production of diagnostic product ions related to the steroid moiety, the latter was preferably selected between methoxamine and hydroxylamine upon the model compounds of androsterone glucuronide and androsterone sulfate. Sixteen different glucuronides and 29 sulfate conjugated metabolites of anabolic androgenic steroids (AASs), available either as pure reference materials or synthesized/extracted from administration studies, were derivatized with GRT, and their product ion spectra are presented. Product ion spectra include in all cases high number of product ions that in some cases are characteristic for certain structures of the steroid backbone. More specifically, preliminary results have shown major differences in fragmentation pattern for 17α/17β-isomers of the sulfate conjugates, but limited differentiation for 17α/17β-isomers of glucuronide conjugates and for 3α/3β- and 5α/5β-stereoisomers of both sulfate and glucuronide conjugates. Further to the suggestion of the current work, application on mesterolone administration studies confirmed-according to the World Anti-Doping Agency (WADA) TD2015IDCR-the presence of seven intact phase II metabolites, one glucuronide and six sulfates with use of LC-ESI-MS/(MS).
Collapse
Affiliation(s)
- Polyxeni Kiousi
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Center for Scientific Research "Demokritos", Athens, Greece
| | - Argyro G Fragkaki
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Center for Scientific Research "Demokritos", Athens, Greece
| | - Nassia Kioukia-Fougia
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Center for Scientific Research "Demokritos", Athens, Greece
| | - Yiannis S Angelis
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Center for Scientific Research "Demokritos", Athens, Greece
| |
Collapse
|
4
|
Sakellariou P, Kiousi P, Fragkaki AG, Lyris E, Petrou M, Georgakopoulos C, Angelis YS. Alternative markers for Methylnortestosterone misuse in human urine. Drug Test Anal 2020; 12:1544-1553. [DOI: 10.1002/dta.2887] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 06/24/2020] [Accepted: 06/25/2020] [Indexed: 02/03/2023]
Affiliation(s)
- Panagiotis Sakellariou
- Doping Control Laboratory of Athens Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos" Neratziotissis & Amaryssias Artemidos Str Athens 15123 Greece
- Faculty of Biology, Schoole of Science National and Kapodistrian University of Athens Panepistimioupolis, Zografou Athens 15771 Greece
| | - Polyxeni Kiousi
- Doping Control Laboratory of Athens Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos" Neratziotissis & Amaryssias Artemidos Str Athens 15123 Greece
| | - Argyro G. Fragkaki
- Doping Control Laboratory of Athens Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos" Neratziotissis & Amaryssias Artemidos Str Athens 15123 Greece
| | - Emmanouil Lyris
- Novartis Technical Operations, Biotechnology & Aseptics, Sandoz GmbH, Schaftenau site Biochemiestrasse 10, Bau 531, 6336 Langkampfen Langkampfen AT Austria
| | - Michael Petrou
- Cyprus Anti‐Doping Authority Makarion Athletic Center Avenue, Engomi Nicosia CY 2400 Cyprus
| | | | - Yiannis S. Angelis
- Doping Control Laboratory of Athens Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos" Neratziotissis & Amaryssias Artemidos Str Athens 15123 Greece
| |
Collapse
|
5
|
Fragkaki AG, Petropoulou G, Athanasiadou I, Kiousi P, Kioukia‐Fougia N, Archontaki H, Bakeas E, Angelis YS. Determination of anabolic androgenic steroids as imidazole carbamate derivatives in human urine using liquid chromatography–tandem mass spectrometry. J Sep Sci 2020; 43:2154-2161. [DOI: 10.1002/jssc.202000036] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 02/25/2020] [Accepted: 02/26/2020] [Indexed: 12/31/2022]
Affiliation(s)
- Argyro G. Fragkaki
- Doping Control Laboratory of AthensInstitute of Biosciences & ApplicationsNational Center for Scientific Research “Demokritos” Athens Greece
| | - Georgia Petropoulou
- Doping Control Laboratory of AthensInstitute of Biosciences & ApplicationsNational Center for Scientific Research “Demokritos” Athens Greece
- Laboratory of Analytical ChemistryDepartment of ChemistryNational & Kapodistrian University of Athens Athens Greece
| | | | - Polyxeni Kiousi
- Doping Control Laboratory of AthensInstitute of Biosciences & ApplicationsNational Center for Scientific Research “Demokritos” Athens Greece
| | - Nassia Kioukia‐Fougia
- Doping Control Laboratory of AthensInstitute of Biosciences & ApplicationsNational Center for Scientific Research “Demokritos” Athens Greece
| | - Helen Archontaki
- Laboratory of Analytical ChemistryDepartment of ChemistryNational & Kapodistrian University of Athens Athens Greece
| | - Evangelos Bakeas
- Laboratory of Analytical ChemistryDepartment of ChemistryNational & Kapodistrian University of Athens Athens Greece
| | - Yiannis S. Angelis
- Doping Control Laboratory of AthensInstitute of Biosciences & ApplicationsNational Center for Scientific Research “Demokritos” Athens Greece
| |
Collapse
|
6
|
Fragkaki AG, Sakellariou P, Kiousi P, Kioukia-Fougia N, Tsivou M, Petrou M, Angelis Y. Human in vivo metabolism study of LGD-4033. Drug Test Anal 2020; 12:164. [PMID: 31984662 DOI: 10.1002/dta.2700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
7
|
Fragkaki AG, Sakellariou P, Kiousi P, Kioukia-Fougia N, Tsivou M, Petrou M, Angelis Y. Human in vivo metabolism study of LGD-4033. Drug Test Anal 2018; 10:1635-1645. [PMID: 30255601 DOI: 10.1002/dta.2512] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2018] [Revised: 09/19/2018] [Accepted: 09/20/2018] [Indexed: 12/13/2022]
Abstract
Selective androgen receptor modulators (SARMs) are an emerging class of therapeutics targeted to cachexia, sarcopenia, and hypogonadism treatment. LGD-4033 is a SARM which has been included on the Prohibited List annually released by the World Anti-Doping Agency (WADA). The aim of the present work was the investigation of the metabolism of LGD-4033 in a human excretion study after administration of an LGD-4033 supplement, the determination of the metabolites' excretion profiles with special interest in the determination of its long-term metabolites, and the comparison of the excretion time of the phase I and phase II metabolites. The results were also compared to those derived from previous LGD-4033 studies concerning both in vitro and in vivo experiments. Supplement containing LGD-4033 was administered to one human male volunteer and urine samples were collected up to almost 21 days. Analysis of the hydrolyzed (with β-glucuronidase) as well as of the non-hydrolyzed samples was performed using liquid chromatography-high resolution mass spectrometry (LC-HRMS) in negative ionization mode and revealed that, in both cases, the two isomers of the dihydroxylated metabolite (M5) were preferred target metabolites. The gluco-conjugated parent LGD-4033 and its gluco-conjugated metabolites M1 and M2 can be also considered as useful target analytes in non-hydrolyzed samples. The study also presents two trihydroxylated metabolites (M6) identified for the first time in human urine; one of them was recently reported in an LGD-4033 metabolism study in horse urine and plasma.
Collapse
Affiliation(s)
- Argyro G Fragkaki
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", 37 Kifisias Avenue, 15123, Maroussi, Greece
| | - Panagiotis Sakellariou
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", 37 Kifisias Avenue, 15123, Maroussi, Greece.,Faculty of Biology, School of Science, National and Kapodistrian University of Athens, Panepistimioupolis, Zografou, 15771, Athens, Greece
| | - Polyxeni Kiousi
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", 37 Kifisias Avenue, 15123, Maroussi, Greece
| | - Nassia Kioukia-Fougia
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", 37 Kifisias Avenue, 15123, Maroussi, Greece
| | - Maria Tsivou
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", 37 Kifisias Avenue, 15123, Maroussi, Greece
| | - Michael Petrou
- Cyprus Anti-Doping Authority, Makarion Athletic Centre Avenue, Engomi, Nicosia, CY, 2400, Cyprus
| | - Yiannis Angelis
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", 37 Kifisias Avenue, 15123, Maroussi, Greece
| |
Collapse
|
8
|
Kiousi P, Angelis YS, Fragkaki AG, Abushareeda W, Alsayrafi M, Georgakopoulos C, Lyris E. Markers of mesterolone abuse in sulfate fraction for doping control in human urine. J Mass Spectrom 2015; 50:1409-1419. [PMID: 26634976 DOI: 10.1002/jms.3715] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Revised: 10/05/2015] [Accepted: 10/08/2015] [Indexed: 06/05/2023]
Abstract
This manuscript describes the direct detection of mesteroloe sulfo-conjugated metabolites by liquid chromatography/quadrupole/time of flight mass spectrometry (LC/Q/TOFMS) with special focus on evaluation of their retrospective detectability and their structure elucidation. A comparison of their long-term detectability, with the mesterolone main metabolite (1α-methyl-5α-androstan-3α-ol-17-one) excreted in glucuronide fraction and detected by gas chromatography/high resolution mass spectrometry (GC/HRMS), is also presented. Studies on mesterolone were performed with samples obtained from two excretion studies after single oral administration of Proviron© by healthy volunteers. Potential sulfate metabolites were detected in post administration samples after liquid-liquid extraction (LLE) with ethyl acetate and LC/TOFMS analysis, in negative mode. Twelve mesterolone sulfate metabolites from the first excretion study and nine from the second were subsequently confirmed by LC/Q/TOFMS. Finally, six mesterolone sulfate metabolites were considered important taking into account their abundance and long-term detectability, encoded as M1, M2, M4, M5, M6 and M7. The proposed mesterolone sulfate metabolites M1, M2, M4 and M5 (excreted as sulfates) have the same retrospectivity with the main mesterolone metabolite, excreted in glucuronide fraction. For metabolite characterization, LC fractionation was performed. The metabolites were identified and characterized by GC/MS, after solvolysis and derivatization. Combined mass spectra data from trimethyl-silyl (TMS), TMS-enolTMS and methoxime-TMS derivatives were taken into account for the characterization of these metabolites. It was concluded that M1 is 1α-methyl-5α-androstan-3β-ol-17 one, M2 is 1α-methyl-5α-androstan-3α-ol-17 one, M4 is 1α-methyl-5a-androstan-3β, 16z-diol-17-one, M5 is 1α-methyl-5α-androstan-17z,4ξ-diol-3one, M6 is 1α-methyl-5α-androstan-3z,6z-diol-17-one and M7 is 4z-hydroxy-1α-methyl-5α-androstan-3,17-dione.
Collapse
Affiliation(s)
- P Kiousi
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens 'Spyros Louis', 37 Kifisias Avenue, 15123, Maroussi, Greece
| | - Y S Angelis
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens 'Spyros Louis', 37 Kifisias Avenue, 15123, Maroussi, Greece
| | - A G Fragkaki
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens 'Spyros Louis', 37 Kifisias Avenue, 15123, Maroussi, Greece
| | - W Abushareeda
- Anti-Doping Laboratory of Qatar, PO Box 27775, Doha, Qatar
| | - M Alsayrafi
- Anti-Doping Laboratory of Qatar, PO Box 27775, Doha, Qatar
| | | | - E Lyris
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens 'Spyros Louis', 37 Kifisias Avenue, 15123, Maroussi, Greece
| |
Collapse
|
9
|
Fragkaki AG, Angelis YS, Kiousi P, Georgakopoulos CG, Lyris E. Comparison of sulfo-conjugated and gluco-conjugated urinary metabolites for detection of methenolone misuse in doping control by LC-HRMS, GC-MS and GC-HRMS. J Mass Spectrom 2015; 50:740-748. [PMID: 26259657 DOI: 10.1002/jms.3583] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Revised: 02/20/2015] [Accepted: 02/21/2015] [Indexed: 06/04/2023]
Abstract
Methenolone (17β-hydroxy-1-methyl-5α-androst-1-en-3-one) misuse in doping control is commonly detected by monitoring the parent molecule and its metabolite (1-methylene-5α-androstan-3α-ol-17-one) excreted conjugated with glucuronic acid using gas chromatography-mass spectrometry (GC-MS) and liquid chromatography mass spectrometry (LC-MS) for the parent molecule, after hydrolysis with β-glucuronidase. The aim of the present study was the evaluation of the sulfate fraction of methenolone metabolism by LC-high resolution (HR)MS and the estimation of the long-term detectability of its sulfate metabolites analyzed by liquid chromatography tandem mass spectrometry (LC-HRMSMS) compared with the current practice for the detection of methenolone misuse used by the anti-doping laboratories. Methenolone was administered to two healthy male volunteers, and urine samples were collected up to 12 and 26 days, respectively. Ethyl acetate extraction at weak alkaline pH was performed and then the sulfate conjugates were analyzed by LC-HRMS using electrospray ionization in negative mode searching for [M-H](-) ions corresponding to potential sulfate structures (comprising structure alterations such as hydroxylations, oxidations, reductions and combinations of them). Eight sulfate metabolites were finally detected, but four of them were considered important as the most abundant and long term detectable. LC clean up followed by solvolysis and GC/MS analysis of trimethylsilylated (TMS) derivatives reveal that the sulfate analogs of methenolone as well as of 1-methylene-5α-androstan-3α-ol-17-one, 3z-hydroxy-1β-methyl-5α-androstan-17-one and 16β-hydroxy-1-methyl-5α-androst-1-ene-3,17-dione were the major metabolites in the sulfate fraction. The results of the present study also document for the first time the methenolone sulfate as well as the 3z-hydroxy-1β-methyl-5α-androstan-17-one sulfate as metabolites of methenolone in human urine. The time window for the detectability of methenolone sulfate metabolites by LC-HRMS is comparable with that of their hydrolyzed glucuronide analogs analyzed by GC-MS. The results of the study demonstrate the importance of sulfation as a phase II metabolic pathway for methenolone metabolism, proposing four metabolites as significant components of the sulfate fraction.
Collapse
Affiliation(s)
- A G Fragkaki
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens 'Spyros Louis', 37 Kifisias Avenue, 15123, Marousi, Greece
| | - Y S Angelis
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens 'Spyros Louis', 37 Kifisias Avenue, 15123, Marousi, Greece
| | - P Kiousi
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens 'Spyros Louis', 37 Kifisias Avenue, 15123, Marousi, Greece
| | | | - E Lyris
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens 'Spyros Louis', 37 Kifisias Avenue, 15123, Marousi, Greece
| |
Collapse
|
10
|
Fragkaki AG, Georgakopoulos C, Sterk S, Nielen MWF. Sports doping: emerging designer and therapeutic β2-agonists. Clin Chim Acta 2013; 425:242-58. [PMID: 23954776 DOI: 10.1016/j.cca.2013.07.031] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2013] [Revised: 07/30/2013] [Accepted: 07/31/2013] [Indexed: 12/12/2022]
Abstract
Beta2-adrenergic agonists, or β2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptom-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of β2-agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006-2012) literature concerning the development of novel β2-agonists molecules either by modifying the molecule of known β2-agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging β2-agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future.
Collapse
Affiliation(s)
- A G Fragkaki
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", Kifisias 37, 15123 Maroussi, Greece.
| | | | | | | |
Collapse
|
11
|
Fragkaki AG, Angelis YS, Tsantili-Kakoulidou A, Koupparis M, Georgakopoulos C. Schemes of metabolic patterns of anabolic androgenic steroids for the estimation of metabolites of designer steroids in human urine. J Steroid Biochem Mol Biol 2009; 115:44-61. [PMID: 19429460 DOI: 10.1016/j.jsbmb.2009.02.016] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2008] [Revised: 02/13/2009] [Accepted: 02/13/2009] [Indexed: 11/19/2022]
Abstract
Unified metabolism schemes of anabolic androgenic steroids (AAS) in human urine based on structure classification of parent molecules are presented in this paper. Principal components analysis (PCA) was applied to AAS molecules referred in the World Anti-Doping Agency (WADA) list of prohibited substances, resulting to their classification into six distinct groups related to structure features where metabolic alterations usually occur. The metabolites of the steroids participating to these six groups were treated using the Excel(c) classification filters showing that common metabolism routes are derived for each of the above PCA classes, leading to the proposed metabolism schemes of the present study. This rule-based approach is proposed for the prediction of the metabolism of unknown, chemically modified steroids, otherwise named as designer steroids. The metabolites of three known, in the literature, AAS are estimated using the proposed metabolism schemes, confirming that their use could be a useful tool for the prediction of metabolic pathways of unknown AAS.
Collapse
Affiliation(s)
- A G Fragkaki
- Olympic Athletic Center of Athens "Spyros Louis", Kifisias, Maroussi, Greece
| | | | | | | | | |
Collapse
|
12
|
Fragkaki AG, Angelis YS, Koupparis M, Tsantili-Kakoulidou A, Kokotos G, Georgakopoulos C. Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor and to their anabolic and androgenic activities. Applied modifications in the steroidal structure. Steroids 2009; 74:172-97. [PMID: 19028512 DOI: 10.1016/j.steroids.2008.10.016] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2008] [Revised: 10/21/2008] [Accepted: 10/29/2008] [Indexed: 11/21/2022]
Abstract
Anabolic androgenic steroids (AAS) are synthetic derivatives of testosterone introduced for therapeutic purposes providing enhanced anabolic potency with reduced androgenic effects. Androgens mediate their action through their binding to the androgen receptor (AR) which is mainly expressed in androgen target tissues, such as the prostate, skeletal muscle, liver and central nervous system. This paper reviews some of the wide spectrum of testosterone and synthetic AAS structure modifications related to the intended enhancement in anabolic activity. The structural features of steroids necessary for effective binding to the AR and those which contribute to the stipulation of the androgenic and anabolic activities are also presented.
Collapse
Affiliation(s)
- A G Fragkaki
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens Spyros Louis, Kifisias 37, 15123 Maroussi, Greece
| | | | | | | | | | | |
Collapse
|